Dopamine agonists(DA) are a first-line therapy for prolactinomas(PA). However, nearly 10% of prolactinomas do not respond to DA therapy. A considerable number of studies have shown that estrogen plays an important role in the development of prolactinomas. However, the expression of estrogen receptors(ER) in prolactinomas has not been fully explored. Accordingly, we examined the levels of ESR1 and its subtypes Δ5-Del-ESR1 and ESR2 m RNA in prolactinomas. In the present study, we found that ESR1 m RNA levels were significantly lower in women of childbearing age group compared to men(P<0.01) and post-menopausal women(P<0.05). In addition, ESR1 m RNA levels showed a significant positive correlation with the levels of prolactin(PRL). Moreover, ESR1 m RNA levels were significantly lower in noninvasive prolactinomas compared to invasive prolactinomas.
展开▼
